Last reviewed 2026-04-20 · How we verify

Votrient

At a glance

Approved indications

• Renal cell carcinoma
• Sarcoma of soft tissue

Common side effects

• Diarrhea
• Hypertension
• Hair color change
• Nausea
• Fatigue
• Anorexia
• Vomiting
• Decreased weight
• Decreased appetite
• Tumor pain
• Musculoskeletal pain
• Headache

Serious adverse events

• Left ventricular dysfunction
• Hypothyroidism
• Elevated lipase (Grade 3-4)
• Chest pain
• Facial edema

Key clinical trials

• Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery (PHASE2, PHASE3)
• Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors (PHASE1)
• Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery (PHASE3)
• Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors (PHASE2)
• Drug Screening Using Novel IMD in Renal Cell Carcinoma (PHASE1)
• Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz) (PHASE2, PHASE3)
• A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas (PHASE1)
• Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.